High Growth Tech Stocks in the United Kingdom for February 2025

In This Article:

The United Kingdom's stock market has recently experienced some turbulence, with the FTSE 100 index closing lower due to weak trade data from China, highlighting concerns about global economic recovery and its impact on UK companies tied to international markets. In such a challenging environment, identifying high growth tech stocks becomes crucial as they often demonstrate resilience and potential for innovation-driven expansion despite broader market uncertainties.

Top 10 High Growth Tech Companies In The United Kingdom

Name

Revenue Growth

Earnings Growth

Growth Rating

STV Group

13.14%

46.78%

★★★★★☆

Facilities by ADF

48.47%

189.97%

★★★★★☆

Pinewood Technologies Group

20.07%

25.09%

★★★★★☆

Redcentric

5.32%

67.90%

★★★★★☆

YouGov

7.67%

56.01%

★★★★★☆

Windar Photonics

36.65%

46.33%

★★★★★☆

Beeks Financial Cloud Group

22.12%

36.94%

★★★★★☆

Vinanz

113.60%

125.86%

★★★★★☆

Oxford Biomedica

21.20%

92.53%

★★★★★☆

Cordel Group

33.50%

148.58%

★★★★★☆

Click here to see the full list of 43 stocks from our UK High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Craneware

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Craneware plc, along with its subsidiaries, specializes in developing, licensing, and supporting computer software for the U.S. healthcare industry and has a market cap of £672.35 million.

Operations: Craneware focuses on creating software solutions tailored for the U.S. healthcare sector, generating revenue primarily through licensing and support services. The company's offerings are designed to enhance operational efficiency and financial performance for healthcare providers.

Craneware, a player in the UK's high-growth tech sector, particularly within healthcare services, has demonstrated robust performance with an earnings growth of 26.4% last year—outpacing the industry average of 3.6%. Despite this strong performance, its revenue growth projection of 8.4% per year trails behind the broader market expectation of 20% annually. However, Craneware's projected annual earnings increase by a significant 29.6%, well above the UK market forecast of 14.8%. This financial trajectory is complemented by strategic executive appointments aimed at bolstering leadership in navigating evolving healthcare economics and technology landscapes—a move illustrated by recent additions like Susan Nelson from MedStar Health to their board. These leadership enhancements align with Craneware’s focus on maintaining competitive advantage in a rapidly changing sector where technological innovation and effective financial management are crucial for sustainability and growth. The firm's commitment to research and development (R&D), although not quantified here, likely plays a pivotal role in fostering these advancements, ensuring that Craneware not only keeps pace but potentially sets trends within the healthcare tech sphere.